The development of new strategy for "Dendritic cells therapy" in combination with anti-angiogenic therapy for the patients with lung cancer
“树突状细胞疗法”联合抗血管生成治疗肺癌新策略的开发
基本信息
- 批准号:14570554
- 负责人:
- 金额:$ 2.37万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2003
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Dendritic cells (DCs) are identified as the most effective antigen presenting cells and play an important role in anti-tumor immunity. In this report, we investigate the usefulness of new DCs-therapy, which is utilized DCs transduced with soluble flt-1 (VEGF-R1) gene.DCs were easily transduced soluble flt-1 gene and efficiently secreted Flt-1 protein. And the cytotoxicity was rarely occurred after infection. Generally, VEGF are secreted from tumor cells, and prompt tumor angiogenesis. In addition, under the VEGF-added condition, bone marrow cells were suppressed to maturate DCs, and the function and the cell viability of DCs were reduced as a result of this inhibition. Meanwhile, DCs transfected with flt-1 gene could not be affected by the addition of VEGF. In tumor treatment model, flt-1-transduced DCs suppressed the tumor growth compared to lac Z-transduced DCs, DCs or no treatment.When Adenovirus-mediated gene transfer of "Flt-1" is infected into DCs, VEGF is trapped by secretory form of flt-1 released by infected DCs, so the negative signal is blocked and DCs can become mature state and cause potent anti-tumor immunity. So flt-1 gene transfer into DCs may be very useful for not only antiangionic effect but also preservation of their maturation under the existence of VEGF.This strategy may thus offer significant benefits for DCs-therapy for patients with cancer.
树突状细胞(Dendritic cells,DC)是目前发现的最有效的抗原提呈细胞,在抗肿瘤免疫中发挥重要作用。本研究以可溶性flt-1基因(soluble flt-1,VEGF-R1)为靶基因,通过转染可溶性flt-1基因并高效分泌Flt-1蛋白的DCs,探讨其在肿瘤治疗中的作用。感染后很少发生细胞毒性反应。通常,VEGF由肿瘤细胞分泌,并促进肿瘤血管生成。此外,在VEGF添加条件下,骨髓细胞被抑制以使DC成熟,并且DC的功能和细胞活力由于这种抑制而降低。转染flt-1基因的DCs对VEGF的表达无明显影响。在肿瘤治疗模型中,转染flt-1的DC与转染lac Z的DC、DC或未处理的DC相比,均能抑制肿瘤的生长,当腺病毒介导的“Flt-1”基因转染DC时,VEGF被感染DC分泌的flt-1所捕获,从而阻断了负信号,使DC成为成熟状态,产生强有力的抗肿瘤免疫。因此,将flt-1基因导入DCs,不仅具有抗血管生成的作用,而且在VEGF的存在下,可以保护DCs的成熟,为DCs治疗肿瘤提供了新的思路。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
T Minami, Y Nakanishi et al.: "Enhancement of antigen presenting capacity and anti-tumor immunity of dendritic cells pulsed with antologous tumor derived RNA in mice."Journal of immunotherapy. 26(4). 420-431 (2003)
T Minami、Y Nakanishi 等人:“小鼠中用原源肿瘤来源的 RNA 脉冲增强树突状细胞的抗原呈递能力和抗肿瘤免疫力。”免疫治疗杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
N, Inoshima, Y, Nakanishi et al.: "The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer."Clin.Can, Res.. 8(10). 3480-3486 (2002)
N,Inoshima,Y,Nakanishi 等:“树突状细胞浸润和血管内皮生长因子表达对非小细胞肺癌预后的影响。”Clin.Can,Res.. 8(10)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
T, Minami, Y, Nakanishi et al.: "Enhancement of antigen presenting capacity and anti-tumor immunity of dendritic cells pulsed with autologous tumor derived RNA in mice."Journal of immunotherapy.. 26(4). 420-431 (2003)
T、Minami、Y、Nakanishi 等人:“小鼠中用自体肿瘤来源的 RNA 脉冲增强树突状细胞的抗原呈递能力和抗肿瘤免疫力。”免疫治疗杂志.. 26(4)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
T, Minami, Y, Nakanishi et al.: "Enhancement of antigen presenting capacity and anti-tumor immunity of dendritic cells pulsed with autologous tumor derived RNA in mice."Journal of immunotherapy. 26(4). 420-431 (2003)
T、Minami、Y、Nakanishi 等人:“小鼠中用自体肿瘤来源的 RNA 脉冲增强树突状细胞的抗原呈递能力和抗肿瘤免疫力。”免疫治疗杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
N, Inoshima, Y, Nakanishi et al.: "The influence of dendritic cell infiltration. and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer."Gun Cancer Res.. 8(11). 3480-3486 (2002)
N、Inoshima、Y、Nakanishi 等人:“树突状细胞浸润和血管内皮生长因子表达对非小细胞肺癌预后的影响。”Gun Cancer Res. 8(11)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAKANISHI Yoichi其他文献
NAKANISHI Yoichi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAKANISHI Yoichi', 18)}}的其他基金
A new methodology to elucidate a molecular function of a membrane transporter gene in plant genome
阐明植物基因组膜转运蛋白基因分子功能的新方法
- 批准号:
24651213 - 财政年份:2012
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Moleclar genetic analysis of eukaryotic molybdate transport systems in a model yeast Hansenula polymorpha and a model animal cell
模型酵母汉逊酵母和模型动物细胞中真核钼酸盐转运系统的分子遗传分析
- 批准号:
22780089 - 财政年份:2010
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Whole genome screening of plant membrane transporter for inorganic elements
植物膜无机元素转运蛋白的全基因组筛选
- 批准号:
20200031 - 财政年份:2008
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research on Innovative Areas (Research a proposed research project)
Analysis of mutants and genes related to eukaryotic molybdenum transport.
与真核钼转运相关的突变体和基因分析。
- 批准号:
20780073 - 财政年份:2008
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of lung cancer treatment strategy using dendritic cells expressing anti-angiogenic function
利用表达抗血管生成功能的树突状细胞开发肺癌治疗策略
- 批准号:
16590752 - 财政年份:2004
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANALYSIS OF CHROMOSOMAL AND CANCER RELATED GENE ABNORMALITIES IN ATYPICAL EPITHELIUM IN THE RESPIRATORY SYSTEM
呼吸系统非典型上皮染色体和癌症相关基因异常分析
- 批准号:
12670562 - 财政年份:2000
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Comparative study on female lung cancer in Japan, USA, China
日本、美国、中国女性肺癌比较研究
- 批准号:
03042015 - 财政年份:1991
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for international Scientific Research
相似海外基金
Development of a novel cancer immunotherapy model targeting human macrophages
开发针对人类巨噬细胞的新型癌症免疫治疗模型
- 批准号:
24K18516 - 财政年份:2024
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Engineering Biology for the Treatment of Solid Tumours : Enhancing T Cell Function and Longevity in the Tumour Microenvironment for Improved Cancer Immunotherapy
治疗实体瘤的工程生物学:增强肿瘤微环境中的 T 细胞功能和寿命,以改善癌症免疫治疗
- 批准号:
10074648 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
Grant for R&D
Structural basis of diacylglycerol kinase alpha, a novel target for cancer immunotherapy
癌症免疫治疗新靶点二酰甘油激酶α的结构基础
- 批准号:
23K05659 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Strategies to predict and overcome resistance to cancer immunotherapy
预测和克服癌症免疫治疗耐药性的策略
- 批准号:
10638167 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
In vivo delivery of Ab-directed CRISPR ribonucleoproteins for anal cancer immunotherapy
用于肛门癌免疫治疗的 Ab 定向 CRISPR 核糖核蛋白的体内递送
- 批准号:
10821884 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
The role of the intestinal microbiome in cancer immunotherapy
肠道微生物组在癌症免疫治疗中的作用
- 批准号:
10738072 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
Exploring bone health in cancer immunotherapy survivors
探索癌症免疫治疗幸存者的骨骼健康
- 批准号:
488249 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
Operating Grants
Preferential on-tumor expression of sticky interleukin-12 for safe local and systemic cancer immunotherapy
粘性白细胞介素 12 在肿瘤上的优先表达,用于安全的局部和全身癌症免疫治疗
- 批准号:
23K11841 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Cell Type-Specific Analysis of Immune Checkpoint Signalling Networks Underpinning Cancer Immunotherapy
支持癌症免疫治疗的免疫检查点信号网络的细胞类型特异性分析
- 批准号:
MR/W025507/1 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
Research Grant